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Abstract
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic
lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-
transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a
haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included;
38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively.
PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years
were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not
statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results
of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an
appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite
the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.
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Introduction
High risk relapsed/refractory (R/R) CLL patients can
nowadays be treated with novel agents targeting various
kinases downstream of the B-cell receptor. The median
progression-free survival (PFS) on the BTK-inhibitor ibru-
tinib for R/R CLL patients with del(17p) is 26 months (95%
CI 18–37) with an estimated 1-year PFS of 80%, while for
all other patients median PFS is at least twice as long [1, 2].
Two-third of these progressive patients have only CLL, the
remainder have a Richter’s transformation at the time of
progression. These latter patients nowadays still have a very
poor prognosis [3]. Patients failing ibrutinib with CLL can
subsequently be treated with idelalisib which results in an
overall response of approximately 35% and a median PFS
of 9 to 12 months [4, 5], or the BCL2 inhibitor venetoclax
which results in an overall response of approximately 70%
and a median PFS that had not been reached yet in two
studies although with a relatively short follow-up
(<12–14 months) [5, 6]. Treatment options in case of
refractoriness of ibrutinib, idelalisib, and venetoclax are
scarce and the outcome is poor.
Allogeneic hematopoietic stem cell transplantation
(alloHCT) may be a valuable option for fit high risk patients
with CLL with del(17) or TP53 mutation or when refractory
to one or more of the new agents. An alloHCT is currently
the only treatment able to achieve longer-lasting PFS
especially in the many patients that achieve MRD-
negativity [7] and its effect is not influenced by the pre-
sence of del(17p), TP53 or other high risk molecular
abnormalities [8, 9]. The fact that MRD-negativity typically
occurs during or after tapering of post-transplantation
immunosuppression and/or in the context of chronic graft
vs. host disease (GVHD) suggests an actual graft vs. leu-
kemia effect [10–12].
In several retrospective registry studies 5-year PFS and
overall survival (OS) after alloHCT for CLL were 36 to
46% [13, 14]. In most patients in these studies HLA-
identical donors were used. Approximately 15 to 20% of
patients lack a HLA-identical sibling or fully HLA-matched
unrelated donor, but very few publications addressed the
issue of using alternative donor sources for alloHCT in
CLL. The use of HLA-mismatched unrelated donors for
CLL patients reduces 3 and 5-year overall survival when
compared to HLA-matched related or unrelated donors as a
result of increased non-relapse mortality [15], while umbi-
lical cord blood transplantation resulted in almost compar-
able 3-year overall survival compared with HLA-matched
transplantations [16]. These effects on outcome of a lower
degree of HLA matching between donor and patient are
seen in various other hematological malignancies too [17].
In recent years the use of haploidentical donors has
substantially increased because the use of post-
transplantation cyclophosphamide (PTCY) after T-cell
replete stem cell transplantation effectively prevents
severe acute GVHD in the majority of patients while
retaining T-cell mediated anti-infectious immunity resulting
in an acceptably low NRM (11–14% after 1–4 years) and
PFS in various hematological malignancies [18, 19]. These
results seem comparable or only slightly inferior to outcome
after matched unrelated donor transplantations [20] and
matched sibling donor transplantations [17], even though
prospective randomized trials are lacking. Up to now no
study specifically focused on the outcome of haploidentical
HCT in CLL patients, while some larger series reporting on
haploidentical HCT with PTCY contained only a few
patients with CLL [17, 21–23].
We now report for the first time on the results of alloHCT
with haploidentical donors in CLL with special emphasis on
the effect of PTCY on relapse given the requirement of
active donor immune cells for an operative graft-vs.-leu-
kemia effect.
Methods
Study design: patients and definitions
All patients aged 18 years or older with CLL who received a
first alloHCT with a related haploidentical donor and whose
data were available in the European Society for Blood and
Marrow Transplantation database between November 1984
and February 2016 were included in this study. All
patients provided informed consent for the registration
and the alloHCT, according to the Declaration of
Helsinki.
The primary endpoint was to describe PFS after haploi-
dentical HCT, defined as time from alloHCT to relapse,
disease progression, or death. The 2 and 5 years after
alloHCT landmarks were selected for reporting point-
estimates. Secondary endpoints were the probability of
OS, defined as the probability of survival regardless of
disease state in any point of time; acute GVHD at day 100;
relapse or progression; and non-relapse mortality (NRM),
defined as death without previous relapse or progression.
The intensity of the conditioning was based on the
reported dosage of drugs and TBI and categorized accord-
ing to published guidelines [24].
Statistical analysis
Median values and ranges are reported for continuous
variables and percentages for categorical variables. The
probabilities of OS and PFS were calculated using the
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Kaplan–Meier method and 95% confidence intervals are
given. A log-rank test was used for univariate comparisons.
P-values <0.05 were considered statistically significant.
Relapse/progression, NRM and acute GVHD were ana-
lyzed in a competing risk framework [25]. The outcomes of
the patients with and without PTCY were compared using a
Gray’s test. Statistical analyses were performed using SPSS
23 and R 3.1.0, packages “survival” and “cmprsk”.
Results
Baseline patient and disease characteristics
Patient and disease characteristics are summarized in
Table 1. One-hundred-seventeen patients with CLL (74%
Table 1 Patient characteristics
Parameter Classification All patients (n= 117)
N (%)
PTCY (n= 40) N
(%)
Patient gender (n= 117/n= 40) Male 86 (74) 27 (68)
Female 31 (26) 13 (32)
Median Age at alloHCT [years] (n=
117/n= 40)
Median (range) 53.5 (27–71) 56.5 (27–68)
Karnofsky Index (n= 98/n= 36) ≥70 94 (96) 35 (97)
<70 4 (4) 1 (3)
Interval CLL diagnosis—alloHCT
[months] (n= 117/n= 40)
Median (range) 67 (4–207) 59 (5–156)
Previous autologous HCT (n= 116/n=
40)
Yes 18 (16) 6 (15)
No 98 (84) 34 (85)
Remission Status at alloHCT (n= 110/
n= 38)
Complete Remission 17 (16) 10 (26)
Partial Remission 43 (39) 15 (40)
Stable disease 15 (13) 5 (13)
Progressive disease 35 (32) 8 (21)
Table 2 Transplantation
characteristics
Parameter Classification All patients N (%) PTCY N (%)
Year of alloHCT (n= 117/n= 40) 1984–1999 10 (9) 0
2000–2004 18 (15) 0
2005–2009 23 (20) 0
2010–2016 66 (56) 40 (100)
Stem cell source (n= 117/n= 40) PB 79 (68) 17 (42)
BM 38 (32) 23 (58)
Conditioning regimen (n= 112/n=
39)
MAC 47 (42) 17 (44)
RIC 65 (58) 22 (56)
Recipient-Donor sex-match (n= 116/
n= 39)
Patient male – Donor male 54 (46) 15 (38)
Patient male – Donor female 31 (27) 11 (28)
Patient female – Donor male 16 (14) 8 (21)
Patient female – Donor
female
15 (13) 5 (13)
Recipient CMV-status (n= 93/n= 37) Patient negative 19 (20) 4 (11)
Patient positive 74 (80) 33 (89)
Donor CMV-status (n= 92/n= 37) Donor negative 37 (40) 15 (41)
Donor positive 55 (60) 22 (59)
Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia 257
males) underwent a mismatched related donor transplanta-
tion between 1984 and 2015 (1984–1999: 10, 2000–2004:
18, 2005–2009: 23, 2010–2016: 66). Median follow up of
patients alive after HCT in the whole cohort was
37.6 months (range 2–187 months); the median follow up of
the patients alive after HCT with PTCY was 30.5 months
(range 2–67 months). Median age at transplantation was 54
years (yrs) (range 27–71 yrs). Median time from diagnosis
to HCT was 67 months (range 4–207 months). Eighteen
patients (15%) had previously undergone autologous HCT
(ASCT). Disease status at HCT was complete remission
(CR) in 16%, partial remission (PR) in 39%, stable
disease (SD) in 13% and progressive disease (PD)
in 32%. Karnofsky score was known for 98 patients (84%),
of these 96% had a score of 70 or more at the time
of HCT.
Baseline transplantation characteristics
Transplantation characteristics are summarized in Table 2.
Fifty-eight percent of patients received reduced-intensity
conditioning, 42% myeloablative conditioning. Peripheral
blood stem cells were used in 68% of patients, bone
marrow in 32%. HCT was sex-matched in 59% of
recipient-donor pairs. Forty patients (38%) received
PTCY as GVHD prophylaxis. The characteristics of those
patients are specified in Tables 1 and 2. Confounders were
equally spread amongst patients with and without PTCY,
except all the patients with PTCY were transplanted in the
latest time period. In the other 77 patients various
other methods of GVHD prevention were used,
for example in vitro T cell depletion, ATG and
alemtuzumab.
Transplantation Outcomes
Graft vs. host disease (GVHD)
The cumulative incidence (CI) of acute GVHD at 100 days
was 32% for grade II-IV and 16% for grade III-IV with a
median time of onset of 23 days (range 4–57 days). The CI
of acute GVHD at 100 days with or without PTCY were
similar for grade II-IV (28 vs. 31%, p= 0.59). The CI of
severe acute GVHD (grade III/IV) were also not sig-
nificantly different with or without the use of PTCY (11 vs.
17%, p= 0.37).
Non-relapse mortality (NRM)
Forty-seven patients experienced non-relapse mortality,
causes of death were mostly transplantation-related (26 died
of infection, 11 of GVHD, 2 of organ failure, 2 of toxicity, 2
of myocardial infarction, 1 of a secondary malignancy, 1 of
a cerebral lesion of unknown origin, 1 of bleeding, 1
unknown HCT related). The cumulative incidence of NRM
at 2 yrs was 40% (95% CI 30–50%) and at 5 yrs 44% (95%
CI 34–54%). The CI of NRM and at 2 and 5 yrs were not
statistically different in patients who received PTCY com-
pared to other types of GHVD prevention (NRM: 39%
(95% CI 23–55%) vs. 42% (95% CI 29–55%) at 2 yrs, 43%
(95% CI 26–60%) vs. 47% (95% CI 33–60%) at 5 yrs, p=
0.72).
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Relapse or progression
The cumulative incidence of relapse or progression at 2 and
5 yrs were 22% (95% CI 13–30%) and 26% (95% CI
16–35%), respectively. Median time to relapse or progres-
sion was 3.4 months (range 0.5–118.2 months).
The cumulative incidence of relapse at 2 and 5 yrs were
not statistically different in patients who received PTCY
compared to other types of GVHD prevention (17% (95%
CI 4–30%) vs. 25% (95% CI 13–36%) at 2 yrs, 17% (95%
CI 4–30%) vs. 30% (95% CI 17–43%) at 5 yrs, p= 0.34).
Overall, 25 patients relapsed or progressed after mis-
matched related HCT. Of these patients, 8 were alive at last
follow-up and 17 died.
Overall survival (OS) and progression-free survival (PFS)
The probabilities of OS at 2 and 5 yrs were 48% (95% CI
37–58%) and 38% (95% CI 27–49%), respectively (Fig. 1).
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PFS at 2 and 5 yrs was 38% (95% CI 28–48%) and 30%
(95% CI 20–41%), respectively (Fig. 2). Overall, 73 of the
117 patients died or relapsed.
In univariate analysis, the use of PTCY vs. other GVHD
prophylactic methods did not have a significant impact on
PFS (44% (95% CI 27–61%) vs. 34% (95% CI 20–47%) at
2 yrs, 40% (95% CI 22–57%) vs. 24% (95% CI 11–36%) at
5 yrs, p= 0.27) (Fig. 3) and OS (48% (95% CI 31–65%) vs.
45% (95% CI 32–59%) at 2 yrs, 43% (95% CI 26–61%) vs.
36% (95% CI 22-%) at 5 yrs, p= 0.63) (Fig. 4).
Univariate analysis did not show a statistically significant
impact on 2-year PFS and OS of patient age (≤53 vs. >53
years old), type of conditioning (MAC or RIC), recipient
donor gender match (female donor for male patients vs. all
others), patient CMV status, stem cell source (PB or BM)
and autologous transplantation before HCT.
Disease status (responsive disease (CR/PR) vs. non-
responsive disease (SD/PD) at HCT had a very significant
impact on PFS and OS. PFS at 2 yrs was 51% (95% CI
36–66%) for responsive disease and 22% (95% CI 9–34%) for
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no-responsive disease, PFS at 5 yrs was 48% (95% CI
33–64%) for responsive disease and 13% (95% CI 3–24%) for
non-responsive disease (p< 0.001) (Fig. 5). OS at 2 yrs was
66% (95% CI 52–79%) for responsive disease and 26% (95%
CI 12–40%) for non-responsive disease, OS at 5 yrs was 57%
(95% CI 40–73%) for responsive disease and 15% (95% CI
3–26%) for non-responsive disease (p< 0.001) (Fig. 6).
Discussion
This is the first study that focused on outcomes of haploi-
dentical HCT for CLL patients.
Long-term outcome (5 yr PFS/OS) of haploidentical
HCT in CLL was in the same range to other publications on
alloHCT in CLL patients where mostly HLA-identical
donors were used [13, 14] and this holds also true for the 40
patients that received PTCY as GVHD prophylaxis.
The use of PTCY seemed not to have a negative impact
on the cumulative incidence of relapse as it seems identical
to the reports on outcome after HLA-matched HCT where
patients had similar baseline characteristics [13, 14].
NRM was higher in this study than in the publications on
alloHCT in CLL where mostly HLA-identical donors were
used [13, 14], but comparable to the results with UCBT and
mismatched unrelated alloHCT [15]. The NRM in our study
was also higher than described in other publications about
haploidentical transplantations using PTCY [18, 19, 26],
but in those studies patients were younger and were mostly
in complete remission. NRM found in our study was
comparable with studies on haploidentical HCT with
in vivo T-cell depleted grafts [27–29].
The incidence of both grade II-IV and grade III-IV acute
GVHD was comparable with other studies on HCT in CLL
[13, 15, 30] and slightly lower than with UBCT in CLL
[16]. The incidence of severe acute GVHD after PTCY was
slightly higher than described in other publications on
haploidentical HCT with use of PTCY [18, 19], but this
could be just a coincidence due to the small amount of
patients in this group.
In other studies, several risk factors have been identified
for a poor outcome of alloHCT in CLL patients [13–15].
These include higher age, lower performance status, unre-
lated donor type, unfavorable sex-mismatch (female donor
to male patient), prior autologous transplantation and
remission status at transplantation [13]. In our study both
PFS and OS were significantly better in patients with
responsive disease compared to patients with non-
responsive disease at transplantation. This was also the
risk factor that had the highest HR for relapse and poor
outcome in earlier studies [13]. Other risk factors (prior
autologous HCT, lower performance status, unfavorable
sex-mismatch and CMV status of patients) regarding the
prognosis could not be identified in this small group of
patients, but in earlier studies the impact of these factors
was much lower than disease status at transplantation.
The availability of kinase and BCL2 inhibitors resulted
in a decrease in the number of transplants because of their
efficacy and relatively good tolerability. A subgroup of
patients with del(17p)/TP53 mutation or being refractory to
one or more of the new drugs may still benefit from
alloHCT. The timing of alloHCT in these patients depends
on the expected benefit from alloHCT, especially with
respect to NRM, above that of continuing the (sequential)
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use of the new drugs. The results of alloHCT appeared to be
better for fit younger patients in remission and having a
HLA- and, in case of males, sex-matched donor [13, 14]. A
higher risk of NRM after alloHCT is however acceptable
when patients become refractory or intolerable to two or
more of the new drugs as the response rate and PFS seems
lower when applied sequentially [5, 6]. In this case the use
of alternative donors, including haploidentical, seems
appropriate based on the results of this study. The best
moment to perform the alloHCT is when the patients is in
remission, since the results of patients with refractory or
stable disease at HCT are dismal.
In conclusion, this retrospective multi-center analysis
shows reasonable outcomes of CLL patients when trans-
planted with a haploidentical donor. Thereby, alloHCT
with a haploidentical donor may be considered in patients
with high-risk CLL and otherwise good risk transplanta-
tion characteristics that are refractory on kinase inhibitors
and/or a BCL2 inhibitor. The use of PTCY as GVHD
prevention seems not to compromise outcome in this
setting.
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